However, recent studies have shown that NSE levels can also be elevated in patients with non‐small cell lung cancer (NSCLC), particularly in subgroups characterized by neuroendocrine differentiation or aggressive biological behavior, drawing increasing clinical attention. Here, ENO2 is linked to non-small cell lung carcinoma.